Artículo
Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer
Mercogliano, María Florencia
; Inurrigarro, Gloria; de Martino, Mara
; Venturutti, Leandro
; Rivas, Martin Alfredo
; Cordo Russo, Rosalia Ines
; Proietti Anastasi, Cecilia Jazmín
; Fernandez, Elmer Andres
; Frahm, Isabel; Barchuk, Sabrina; Allemand, Daniel H.; Figurelli, Silvina; Gil Deza, Ernesto; Ares, Sandra; Gercovich, Felipe G.; Cortese, Eduardo; Amasino, Matías; Guzmán, Pablo; Roa, Juan C.; Elizalde, Patricia Virginia
; Schillaci, Roxana
Fecha de publicación:
12/2017
Editorial:
BioMed Central
Revista:
BMC Cancer
ISSN:
1471-2407
e-ISSN:
1471-2407
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Invasive micropapillary carcinoma of the breast (IMPC) is a histological tumor variant that occurs with low frequency characterized by an inside-out formation of tumor clusters with a pseudopapillary arrangement. IMPC is an aggressive tumor with poor clinical outcome. In addition, this histological subtype usually expresses human epidermal growth factor receptor 2 (HER2) which also correlates with a more aggressive tumor. In this work we studied the clinical significance of IMPC in HER2-positive breast cancer patients treated with adjuvant trastuzumab. We also analyzed mucin 4 (MUC4) expression as a novel biomarker to identify IMPC.
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IBYME)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Mercogliano, María Florencia; Inurrigarro, Gloria; de Martino, Mara; Venturutti, Leandro; Rivas, Martin Alfredo; et al.; Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer; BioMed Central; BMC Cancer; 17; 1; 12-2017; 895-895
Compartir
Altmétricas